SCHEMBL6261002

SCHEMBL6261002

Cc1cc(C(=O)N2CCN(c3cccc(C(N)=O)c3)CC2)n(-c2cccnc2)n1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
KHK P50053 1/20 0.47
TSHR P16473 1/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 2/20 0.43
PLOD2 O00469 1/20 0.42
PLOD3 O60568 1/20 0.42
PLOD1 Q02809 1/20 0.42
AOC3 Q16853 2/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
GRM1 Q13255 1/20 0.41
MLYCD O95822 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263738 0.89 TSHR (0.56) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL6261726 0.88 ALDH1A1 (0.52) ALDH1A1TSHRHTTPKMSMN1; SMN2
SCHEMBL6262758 0.83 MAPT (0.51) ALDH1A1TSHRHTTMAPTSMN1; SMN2
SCHEMBL6262923 0.83 ALDH1A1 (0.57) ALDH1A1TSHRPKMLMNAMEN1
SCHEMBL6418198 0.81 TSHR (0.60) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL6261073 0.80 TSHR (0.56) ALDH1A1TSHRHTTMAPTSMN1; SMN2
SCHEMBL6262956 0.78 TSHR (0.58) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL6261963 0.78 TSHR (0.53) ALDH1A1TSHRMAPTSMN1; SMN2LMNA
SCHEMBL6416255 0.77 TSHR (0.65) ALDH1A1TSHRHTTMAPTLMNA
SCHEMBL6415443 0.76 TSHR (0.59) ALDH1A1TSHRHTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590329-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2005-11-02 EP disclosed
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-06-16 US disclosed
WO-2004078732-A1 N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130989-A1 N-arylheteroaromatic products compositions containing them and use thereof AHR, NQO1, ARNT ALDH1A1 360/4885KHK 2335/4885TSHR 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.